Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.

Annals of intensive care

Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA.
PMID: 25593740
Ann Intensive Care. 2014 Jul 03;4:22. doi: 10.1186/s13613-014-0022-z. eCollection 2014.

CLINICAL TRIALS REGISTRATION: NCT01775774 and NCT02097641.

Cite
Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014;4:22doi: 10.1186/s13613-014-0022-z.
Liu, K. D., Wilson, J. G., Zhuo, H., Caballero, L., McMillan, M. L., Fang, X., Cosgrove, K., Calfee, C. S., Lee, J. W., Kangelaris, K. N., Gotts, J. E., Rogers, A. J., Levitt, J. E., Wiener-Kronish, J. P., Delucchi, K. L., Leavitt, A. D., McKenna, D. H., Thompson, B. T., & Matthay, M. A. (2014). Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Annals of intensive care, 422. https://doi.org/10.1186/s13613-014-0022-z
Liu, Kathleen D, et al. "Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome." Annals of intensive care vol. 4 (2014): 22. doi: https://doi.org/10.1186/s13613-014-0022-z
Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014 Jul 03;4:22. doi: 10.1186/s13613-014-0022-z. eCollection 2014. PMID: 25593740; PMCID: PMC4273700.
Copy Download .nbib Format: NLM
The authors reply.

Critical care medicine

Kangelaris KN, Ware LB, Matthay MA, Calfee CS.
PMID: 27428148
Crit Care Med. 2016 Aug;44(8):e769-70. doi: 10.1097/CCM.0000000000001910.

No abstract available.

Cite
Kangelaris KN, Ware LB, Matthay MA, et al. The authors reply. Crit Care Med. 2016;44(8):e769-70doi: 10.1097/CCM.0000000000001910.
Kangelaris, K. N., Ware, L. B., Matthay, M. A., & Calfee, C. S. (2016). The authors reply. Critical care medicine, 44(8), e769-70. https://doi.org/10.1097/CCM.0000000000001910
Kangelaris, Kirsten Neudoerffer, et al. "The authors reply." Critical care medicine vol. 44,8 (2016): e769-70. doi: https://doi.org/10.1097/CCM.0000000000001910
Kangelaris KN, Ware LB, Matthay MA, Calfee CS. The authors reply. Crit Care Med. 2016 Aug;44(8):e769-70. doi: 10.1097/CCM.0000000000001910. PMID: 27428148; PMCID: PMC5031148.
Copy Download .nbib Format: NLM
Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19.

medRxiv : the preprint server for health sciences

Tsitsiklis A, Zha BS, Byrne A, Devoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay MA, Lynch SV, DeRisi JL, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR.
PMID: 33791731
medRxiv. 2021 Mar 26; doi: 10.1101/2021.03.23.21253487.

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections. Critically ill patients with coronavirus disease 2019 (COVID-19) face an elevated risk of VAP, although susceptibility varies widely. Because mechanisms...

Cite
Tsitsiklis A, Zha BS, Byrne A, et al. Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021;doi: 10.1101/2021.03.23.21253487.
Tsitsiklis, A., Zha, B. S., Byrne, A., Devoe, C., Levan, S., Rackaityte, E., Sunshine, S., Mick, E., Ghale, R., Jauregui, A., Sarma, A., Neff, N., Serpa, P. H., Deiss, T. J., Kistler, A., Carrillo, S., Ansel, K. M., Leligdowicz, A., Christenson, S., Jones, N., Wu, B., Darmanis, S., Matthay, M. A., Lynch, S. V., DeRisi, J. L., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Erle, D. J., Rosenberg, O., Calfee, C. S., & Langelier, C. R. (2021). Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis, Alexandra, et al. "Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis A, Zha BS, Byrne A, Devoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay MA, Lynch SV, DeRisi JL, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR. Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021 Mar 26; doi: 10.1101/2021.03.23.21253487. PMID: 33791731; PMCID: PMC8010763.
Copy Download .nbib Format: NLM
Global Absence and Targeting of Protective Immune States in Severe COVID-19.

Research square

Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF.
PMID: 33140041
Res Sq. 2020 Oct 28; doi: 10.21203/rs.3.rs-97042/v1.

While SARS-CoV-2 infection has pleiotropic and systemic effects in some patients, many others experience milder symptoms. We sought a holistic understanding of the severe/mild distinction in COVID-19 pathology, and its origins. We performed a wholeblood preserving single-cell analysis protocol...

Cite
Combes AJ, Courau T, Kuhn NF, et al. Global Absence and Targeting of Protective Immune States in Severe COVID-19. Res Sq. 2020;doi: 10.21203/rs.3.rs-97042/v1.
Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Cleary, S. J., Chew, N. W., Kushnoor, D., Reeder, G. C., Shen, A., Tsui, J., Hiam-Galvez, K. J., Muñoz-Sandoval, P., Zhu, W. S., Lee, D. S., Sun, Y., You, R., Magnen, M., Rodriguez, L., Leligdowicz, A., Zamecnik, C. R., Loudermilk, R. P., Wilson, M. R., Ye, C. J., Fragiadakis, G. K., Looney, M. R., Chan, V., Ward, A., Carrillo, S., Matthay, M., Erle, D. J., Woodruff, P. G., Langelier, C., Kangelaris, K., Hendrickson, C. M., Calfee, C., Rao, A. A., & Krummel, M. F. (2020). Global Absence and Targeting of Protective Immune States in Severe COVID-19. Research square, . https://doi.org/10.21203/rs.3.rs-97042/v1
Combes, Alexis J, et al. "Global Absence and Targeting of Protective Immune States in Severe COVID-19." Research square vol. (2020). doi: https://doi.org/10.21203/rs.3.rs-97042/v1
Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF. Global Absence and Targeting of Protective Immune States in Severe COVID-19. Res Sq. 2020 Oct 28; doi: 10.21203/rs.3.rs-97042/v1. PMID: 33140041; PMCID: PMC7605560.
Copy Download .nbib Format: NLM
Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01.

EClinicalMedicine

Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B.
PMID: 34490415
EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02.

BACKGROUND: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen...

Cite
Weiner J, Suwalski P, Holtgrewe M, et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021;40:101099doi: 10.1016/j.eclinm.2021.101099.
Weiner, J., Suwalski, P., Holtgrewe, M., Rakitko, A., Thibeault, C., Müller, M., Patriki, D., Quedenau, C., Krüger, U., Ilinsky, V., Popov, I., Balnis, J., Jaitovich, A., Helbig, E. T., Lippert, L. J., Stubbemann, P., Real, L. M., Macías, J., Pineda, J. A., Fernandez-Fuertes, M., Wang, X., Karadeniz, Z., Saccomanno, J., Doehn, J. M., Hübner, R. H., Hinzmann, B., Salvo, M., Blueher, A., Siemann, S., Jurisic, S., Beer, J. H., Rutishauser, J., Wiggli, B., Schmid, H., Danninger, K., Binder, R., Corman, V. M., Mühlemann, B., Arjun Arkal, R., Fragiadakis, G. K., Mick, E., Comet, C., Calfee, C. S., Erle, D. J., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Langelier, C. R., Venkataramani, U., García, F., Zyla, J., Drosten, C., Alice, B., Jones, T. C., Suttorp, N., Witzenrath, M., Hippenstiel, S., Zemojtel, T., Skurk, C., Poller, W., Borodina, T., Pa-Covid, S. G., Ripke, S., Sander, L. E., Beule, D., Landmesser, U., Guettouche, T., Kurth, F., & Heidecker, B. (2021). Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 40101099. https://doi.org/10.1016/j.eclinm.2021.101099
Weiner, January, et al. "Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01." EClinicalMedicine vol. 40 (2021): 101099. doi: https://doi.org/10.1016/j.eclinm.2021.101099
Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02. PMID: 34490415; PMCID: PMC8410317.
Copy Download .nbib Format: NLM
Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome.

Intensive care medicine

Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, Ware LB, Alkhouli MF, Abbott J, Matthay MA.
PMID: 25708422
Intensive Care Med. 2015 Mar;41(3):574. doi: 10.1007/s00134-015-3703-7.

No abstract available.

Cite
Sapru A, Calfee CS, Liu KD, et al. Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med. 2015;41(3):574doi: 10.1007/s00134-015-3703-7.
Sapru, A., Calfee, C. S., Liu, K. D., Kangelaris, K., Hansen, H., Pawlikowska, L., Ware, L. B., Alkhouli, M. F., Abbott, J., Matthay, M. A. (2015). Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive care medicine, 41(3), 574. https://doi.org/10.1007/s00134-015-3703-7
Sapru, Anil, et al. "Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome." Intensive care medicine vol. 41,3 (2015): 574. doi: https://doi.org/10.1007/s00134-015-3703-7
Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, Ware LB, Alkhouli MF, Abbott J, Matthay MA. Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med. 2015 Mar;41(3):574. doi: 10.1007/s00134-015-3703-7. PMID: 25708422.
Copy Download .nbib Format: NLM
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis.

The Lancet. Respiratory medicine

Maddali MV, Churpek M, Pham T, Rezoagli E, Zhuo H, Zhao W, He J, Delucchi KL, Wang C, Wickersham N, McNeil JB, Jauregui A, Ke S, Vessel K, Gomez A, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Liu KD, Matthay MA, Ware LB, Laffey JG, Bellani G, Calfee CS, Sinha P.
PMID: 35026177
Lancet Respir Med. 2022 Jan 10; doi: 10.1016/S2213-2600(21)00461-6. Epub 2022 Jan 10.

BACKGROUND: Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes,...

Cite
Maddali MV, Churpek M, Pham T, et al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022;doi: 10.1016/S2213-2600(21)00461-6.
Maddali, M. V., Churpek, M., Pham, T., Rezoagli, E., Zhuo, H., Zhao, W., He, J., Delucchi, K. L., Wang, C., Wickersham, N., McNeil, J. B., Jauregui, A., Ke, S., Vessel, K., Gomez, A., Hendrickson, C. M., Kangelaris, K. N., Sarma, A., Leligdowicz, A., Liu, K. D., Matthay, M. A., Ware, L. B., Laffey, J. G., Bellani, G., Calfee, C. S., Sinha, P. (2022). Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. The Lancet. Respiratory medicine, . https://doi.org/10.1016/S2213-2600(21)00461-6
Maddali, Manoj V, et al. "Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis." The Lancet. Respiratory medicine vol. (2022). doi: https://doi.org/10.1016/S2213-2600(21)00461-6
Maddali MV, Churpek M, Pham T, Rezoagli E, Zhuo H, Zhao W, He J, Delucchi KL, Wang C, Wickersham N, McNeil JB, Jauregui A, Ke S, Vessel K, Gomez A, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Liu KD, Matthay MA, Ware LB, Laffey JG, Bellani G, Calfee CS, Sinha P. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022 Jan 10; doi: 10.1016/S2213-2600(21)00461-6. Epub 2022 Jan 10. PMID: 35026177.
Copy Download .nbib Format: NLM
Increased rates of secondary bacterial infections, including .

Infection control and hospital epidemiology

DeVoe C, Segal MR, Wang L, Stanley K, Madera S, Fan J, Schouest J, Graham-Ojo R, Nichols A, Prasad PA, Ghale R, Love C, Abe-Jones Y, Kangelaris KN, Patterson SL, Yokoe DS, Langelier CR.
PMID: 34486503
Infect Control Hosp Epidemiol. 2021 Sep 06;1-8. doi: 10.1017/ice.2021.391. Epub 2021 Sep 06.

OBJECTIVE: We compared the rates of hospital-onset secondary bacterial infections in patients with coronavirus disease 2019 (COVID-19) with rates in patients with influenza and controls, and we investigated reports of increased incidence of Enterococcus infections in patients with COVID-19.DESIGN:...

Cite
DeVoe C, Segal MR, Wang L, et al. Increased rates of secondary bacterial infections, including . Infect Control Hosp Epidemiol. 2021;1-8doi: 10.1017/ice.2021.391.
DeVoe, C., Segal, M. R., Wang, L., Stanley, K., Madera, S., Fan, J., Schouest, J., Graham-Ojo, R., Nichols, A., Prasad, P. A., Ghale, R., Love, C., Abe-Jones, Y., Kangelaris, K. N., Patterson, S. L., Yokoe, D. S., & Langelier, C. R. (2021). Increased rates of secondary bacterial infections, including . Infection control and hospital epidemiology, 1-8. https://doi.org/10.1017/ice.2021.391
DeVoe, Catherine, et al. "Increased rates of secondary bacterial infections, including ." Infection control and hospital epidemiology vol. (2021): 1-8. doi: https://doi.org/10.1017/ice.2021.391
DeVoe C, Segal MR, Wang L, Stanley K, Madera S, Fan J, Schouest J, Graham-Ojo R, Nichols A, Prasad PA, Ghale R, Love C, Abe-Jones Y, Kangelaris KN, Patterson SL, Yokoe DS, Langelier CR. Increased rates of secondary bacterial infections, including . Infect Control Hosp Epidemiol. 2021 Sep 06;1-8. doi: 10.1017/ice.2021.391. Epub 2021 Sep 06. PMID: 34486503; PMCID: PMC8458844.
Copy Download .nbib Format: NLM
Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19.

EClinicalMedicine

Shah SJ, Barish PN, Prasad PA, Kistler A, Neff N, Kamm J, Li LM, Chiu CY, Babik JM, Fang MC, Abe-Jones Y, Alipanah N, Alvarez FN, Botvinnik OB, Castaneda G, Dadasovich RM, Davis J, Deng X, DeRisi JL, Detweiler AM, Federman S, Haliburton J, Hao S, Kerkhoff AD, Kumar GR, Malcolm KB, Mann SA, Martinez S, Mary RK, Mick E, Mwakibete L, Najafi N, Peluso MJ, Phelps M, Pisco AO, Ratnasiri K, Rubio LA, Sellas A, Sherwood KD, Sheu J, Spottiswoode N, Tan M, Yu G, Kangelaris KN, Langelier C.
PMID: 32864588
EClinicalMedicine. 2020 Oct;27:100518. doi: 10.1016/j.eclinm.2020.100518. Epub 2020 Aug 26.

BACKGROUND: Most data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have been presented as case series without comparison to patients with other acute respiratory illnesses.METHODS: We examined emergency department patients between February 3 and March...

Cite
Shah SJ, Barish PN, Prasad PA, et al. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine. 2020;27:100518doi: 10.1016/j.eclinm.2020.100518.
Shah, S. J., Barish, P. N., Prasad, P. A., Kistler, A., Neff, N., Kamm, J., Li, L. M., Chiu, C. Y., Babik, J. M., Fang, M. C., Abe-Jones, Y., Alipanah, N., Alvarez, F. N., Botvinnik, O. B., Castaneda, G., Dadasovich, R. M., Davis, J., Deng, X., DeRisi, J. L., Detweiler, A. M., Federman, S., Haliburton, J., Hao, S., Kerkhoff, A. D., Kumar, G. R., Malcolm, K. B., Mann, S. A., Martinez, S., Mary, R. K., Mick, E., Mwakibete, L., Najafi, N., Peluso, M. J., Phelps, M., Pisco, A. O., Ratnasiri, K., Rubio, L. A., Sellas, A., Sherwood, K. D., Sheu, J., Spottiswoode, N., Tan, M., Yu, G., Kangelaris, K. N., & Langelier, C. (2020). Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine, 27100518. https://doi.org/10.1016/j.eclinm.2020.100518
Shah, Sachin J, et al. "Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19." EClinicalMedicine vol. 27 (2020): 100518. doi: https://doi.org/10.1016/j.eclinm.2020.100518
Shah SJ, Barish PN, Prasad PA, Kistler A, Neff N, Kamm J, Li LM, Chiu CY, Babik JM, Fang MC, Abe-Jones Y, Alipanah N, Alvarez FN, Botvinnik OB, Castaneda G, Dadasovich RM, Davis J, Deng X, DeRisi JL, Detweiler AM, Federman S, Haliburton J, Hao S, Kerkhoff AD, Kumar GR, Malcolm KB, Mann SA, Martinez S, Mary RK, Mick E, Mwakibete L, Najafi N, Peluso MJ, Phelps M, Pisco AO, Ratnasiri K, Rubio LA, Sellas A, Sherwood KD, Sheu J, Spottiswoode N, Tan M, Yu G, Kangelaris KN, Langelier C. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: A retrospective cohort study of patients with and without COVID-19. EClinicalMedicine. 2020 Oct;27:100518. doi: 10.1016/j.eclinm.2020.100518. Epub 2020 Aug 26. PMID: 32864588; PMCID: PMC7447618.
Copy Download .nbib Format: NLM
Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma.

International journal of otolaryngology

Kangelaris GT, Yom SS, Huang K, Wang SJ.
PMID: 20862388
Int J Otolaryngol. 2010;2010. doi: 10.1155/2010/904297. Epub 2010 Aug 31.

Objectives. To determine the utility of routine surveillance MRI in detecting locoregional recurrence following definitive chemoradiation in advanced-stage oropharynx carcinoma. Methods. We identified patients with Stage III-IV oropharynx carcinoma who were treated with chemoradiation between April 2000 and September...

Cite
Kangelaris GT, Yom SS, Huang K, et al. Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma. Int J Otolaryngol. 2010;2010doi: 10.1155/2010/904297.
Kangelaris, G. T., Yom, S. S., Huang, K., & Wang, S. J. (2010). Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma. International journal of otolaryngology, 2010. https://doi.org/10.1155/2010/904297
Kangelaris, Gerald T, et al. "Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma." International journal of otolaryngology vol. 2010 (2010). doi: https://doi.org/10.1155/2010/904297
Kangelaris GT, Yom SS, Huang K, Wang SJ. Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma. Int J Otolaryngol. 2010;2010. doi: 10.1155/2010/904297. Epub 2010 Aug 31. PMID: 20862388; PMCID: PMC2939390.
Copy Download .nbib Format: NLM
Global Absence and Targeting of Protective Immune States in Severe COVID-19.

bioRxiv : the preprint server for biology

Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF.
PMID: 33140050
bioRxiv. 2020 Oct 29; doi: 10.1101/2020.10.28.359935.

While SARS-CoV-2 infection has pleiotropic and systemic effects in some patients, many others experience milder symptoms. We sought a holistic understanding of the severe/mild distinction in COVID-19 pathology, and its origins. We performed a whole-blood preserving single-cell analysis protocol...

Cite
Combes AJ, Courau T, Kuhn NF, et al. Global Absence and Targeting of Protective Immune States in Severe COVID-19. bioRxiv. 2020;doi: 10.1101/2020.10.28.359935.
Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Cleary, S. J., Chew, N. W., Kushnoor, D., Reeder, G. C., Shen, A., Tsui, J., Hiam-Galvez, K. J., Muñoz-Sandoval, P., Zhu, W. S., Lee, D. S., Sun, Y., You, R., Magnen, M., Rodriguez, L., Leligdowicz, A., Zamecnik, C. R., Loudermilk, R. P., Wilson, M. R., Ye, C. J., Fragiadakis, G. K., Looney, M. R., Chan, V., Ward, A., Carrillo, S., Matthay, M., Erle, D. J., Woodruff, P. G., Langelier, C., Kangelaris, K., Hendrickson, C. M., Calfee, C., Rao, A. A., & Krummel, M. F. (2020). Global Absence and Targeting of Protective Immune States in Severe COVID-19. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.10.28.359935
Combes, Alexis J, et al. "Global Absence and Targeting of Protective Immune States in Severe COVID-19." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.10.28.359935
Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF. Global Absence and Targeting of Protective Immune States in Severe COVID-19. bioRxiv. 2020 Oct 29; doi: 10.1101/2020.10.28.359935. PMID: 33140050; PMCID: PMC7605559.
Copy Download .nbib Format: NLM
Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19.

medRxiv : the preprint server for health sciences

Shah SJ, Barish PN, Prasad PA, Kistler AL, Neff N, Kamm J, Li LM, Chiu CY, Babick JM, Fang MC, Abe-Jones Y, Alipanah N, Alvarez FN, Botvinnik OB, Davis JM, Castenada GD, Consortium C, Dadasovich RM, Deng X, DeRisi JL, Detweiler AM, Federman S, Haliburton JR, Hao SL, Kerkhoff AD, Kumar R, Malcolm K, Mann SA, Martinez SP, Marya R, Mick E, Mwakibete LL, Najafi N, Peluso MJ, Phelps MS, Pisco AO, Ratnasiri K, Rubio LA, Sellas AB, Sherwood KD, Sheu J, Spottiswoode N, Tan M, Yu G, Kangelaris KN, Langelier C.
PMID: 32511488
medRxiv. 2020 May 06; doi: 10.1101/2020.05.02.20082461.

BACKGROUND: Emerging data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have largely been presented as case series. Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.METHODS: We examined...

Cite
Shah SJ, Barish PN, Prasad PA, et al. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19. medRxiv. 2020;doi: 10.1101/2020.05.02.20082461.
Shah, S. J., Barish, P. N., Prasad, P. A., Kistler, A. L., Neff, N., Kamm, J., Li, L. M., Chiu, C. Y., Babick, J. M., Fang, M. C., Abe-Jones, Y., Alipanah, N., Alvarez, F. N., Botvinnik, O. B., Davis, J. M., Castenada, G. D., Consortium, C., Dadasovich, R. M., Deng, X., DeRisi, J. L., Detweiler, A. M., Federman, S., Haliburton, J. R., Hao, S. L., Kerkhoff, A. D., Kumar, R., Malcolm, K., Mann, S. A., Martinez, S. P., Marya, R., Mick, E., Mwakibete, L. L., Najafi, N., Peluso, M. J., Phelps, M. S., Pisco, A. O., Ratnasiri, K., Rubio, L. A., Sellas, A. B., Sherwood, K. D., Sheu, J., Spottiswoode, N., Tan, M., Yu, G., Kangelaris, K. N., & Langelier, C. (2020). Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.05.02.20082461
Shah, Sachin J, et al. "Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.05.02.20082461
Shah SJ, Barish PN, Prasad PA, Kistler AL, Neff N, Kamm J, Li LM, Chiu CY, Babick JM, Fang MC, Abe-Jones Y, Alipanah N, Alvarez FN, Botvinnik OB, Davis JM, Castenada GD, Consortium C, Dadasovich RM, Deng X, DeRisi JL, Detweiler AM, Federman S, Haliburton JR, Hao SL, Kerkhoff AD, Kumar R, Malcolm K, Mann SA, Martinez SP, Marya R, Mick E, Mwakibete LL, Najafi N, Peluso MJ, Phelps MS, Pisco AO, Ratnasiri K, Rubio LA, Sellas AB, Sherwood KD, Sheu J, Spottiswoode N, Tan M, Yu G, Kangelaris KN, Langelier C. Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19. medRxiv. 2020 May 06; doi: 10.1101/2020.05.02.20082461. PMID: 32511488; PMCID: PMC7273256.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries